DENVER – TriSalus Life Sciences Inc. (NASDAQ: TLSI), an oncology company specializing in drug delivery technology for liver and pancreatic tumors, has published research demonstrating a significant improvement in the delivery of therapeutic glass microspheres to liver tumors using its Pressure-Enabled Drug Delivery (PEDD) method. The study, featured in the Journal of Vascular and Interventional Radiology, showed a 117% increase in penetration with lobar infusions and a 39% increase with selective infusions compared to traditional methods.
The PEDD method, applied through the company’s TriNav Infusion System, is designed to overcome the challenges of efficiently delivering therapeutics to tumor cells while minimizing impact on healthy tissue. According to Bryan F. Cox, Ph.D., Chief of Research for TriSalus, this method can selectively target multiple tumors simultaneously, which could be beneficial for patients with extensive disease.
The research involved a comparison of the PEDD method with conventional microcatheter delivery in transgenic pigs with induced liver tumors. The findings suggest that the PEDD method could alter hemodynamics and the microenvironment within the liver, leading to higher concentrations of microspheres in the tumor with an equivalent safety profile to selective Y90 treatment.
Mary Szela, CEO and President of TriSalus, underscored the potential of the PEDD approach to address a critical need in cancer care. Dr. Riad Salem, Chief of Interventional Radiology, noted that if these results are replicated in human models, it could mark a significant advancement in liver cancer management.
TriSalus’s technology platform encompasses devices that employ PEDD to deliver various therapeutics and an investigational immunotherapy. The company aims to improve patient outcomes by addressing the immunosuppressive environment created by tumors, which can render current immunotherapies ineffective.
The information presented in this article is based on a press release statement from TriSalus Life Sciences.
In other recent news, TriSalus Life Sciences has been the subject of several analyst ratings. Oppenheimer initiated coverage with an Outperform rating, citing the company’s potential in liver cancer treatment, and set a price target of $10.00. The company’s revenue, annualizing at approximately $30 million with a compound annual growth rate of 40-50%, was highlighted as a strong factor. Additionally, Jones Trading maintained a Buy rating with an $11.00 price target, based on the anticipated clinical benefits of its product Nelitolimod.
Canaccord Genuity also maintained its Buy rating, citing the company’s growth prospects and a price target of $12.00. The firm pointed to the anticipated launch of a larger-sized version of TriSalus’s medical device by the end of 2024, which could increase its addressable market by approximately 25%. TriSalus has also secured a $50 million credit facility with healthcare investment firm OrbiMed, extending its cash runway through 2025.
Lastly, TriSalus recently welcomed Liselotte Hyveled, a veteran in pharmaceutical research and development, to its Board of Directors. These recent developments underscore the company’s potential for growth and strategic initiatives in the oncology sector.
InvestingPro Insights
As TriSalus Life Sciences Inc. (NASDAQ: TLSI) continues to innovate in the field of oncology with its Pressure-Enabled Drug Delivery (PEDD) method, the company’s financial health remains a key factor for investors monitoring its progress. Recent data from InvestingPro provides insights into the company’s financial metrics and stock performance, which may have implications for its ability to sustain research and development efforts.
One of the most notable metrics is the company’s gross profit margin, which stands at an impressive 87.65% for the last twelve months as of Q2 2024. This indicates that TriSalus is highly efficient in converting revenue into gross profit, a positive sign for its operational effectiveness. However, it’s important to note that TriSalus is rapidly depleting its cash reserves, which could pose challenges for future operations if not managed carefully. Additionally, analysts are not expecting the company to be profitable this year, which may be a concern for long-term investors.
The stock performance of TriSalus has shown volatility, with a significant decline of 54.19% over the last six months. This could reflect investor sentiment about the company’s near-term prospects and market conditions. Despite these challenges, TriSalus’s liquid assets do exceed its short-term obligations, suggesting that the company is in a position to meet its immediate financial liabilities.
InvestingPro Tips further reveal that TriSalus operates with a moderate level of debt and does not pay a dividend to shareholders. For investors seeking more comprehensive analysis, there are additional InvestingPro Tips available on the company, which can be found at https://www.investing.com/pro/TLSI.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
